March 30 (Reuters) - Can Fite Biopharma Ltd:
* CAN-FITE REPORTS 2022 FINANCIAL RESULTS & PROVIDES CLINICAL UPDATE
* CAN FITE BIOPHARMA LTD - AS OF DEC 31, 2022, HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM DEPOSITS OF $7.97 MILLION
* CAN FITE BIOPHARMA LTD - FY NET LOSS WAS $10.17 MILLION VERSUS NET LOSS OF $12.61 MILLION
* CAN FITE BIOPHARMA: NAMODENOSON IS SHOWING POTENTIAL FOR EFFICACY ACROSS SEVERAL INDICATIONS FROM LIVER DISEASE TO PANCREATIC CANCER Source text for Eikon: Further company coverage: